Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation & Amortization (2023 - 2025)

Contineum Therapeutics' Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $300000.0 for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 16.28% to $300000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2025, up 16.28% year-over-year, with the annual reading at $300000.0 for FY2025, 16.28% up from the prior year.
  • Accumulated Depreciation & Amortization came in at $300000.0 for Q4 2025, up from $258000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.5 million in Q4 2023 to a low of $258000.0 in Q4 2024.
  • The 3-year median for Accumulated Depreciation & Amortization is $300000.0 (2025), against an average of $678333.3.
  • Year-over-year, Accumulated Depreciation & Amortization tumbled 82.53% in 2024 and then increased 16.28% in 2025.
  • Contineum Therapeutics' Accumulated Depreciation & Amortization stood at $1.5 million in 2023, then crashed by 82.53% to $258000.0 in 2024, then rose by 16.28% to $300000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTNM's Accumulated Depreciation & Amortization are $300000.0 (Q4 2025), $258000.0 (Q4 2024), and $1.5 million (Q4 2023).